Hydroxyurea Tablets
Formulated to target cancerous cell growth and indicated to support blood count regulation, this agent is utilized to manage specific haematologic conditions.
Strengths: 500mg
Where to Check Availability
Medicine details
- Alternative names
Hydrea
- Therapeutic class
Antineoplastic agent
- Pharmacological class
Antimetabolite
- Known off-label uses
sickle cell anaemia
- Contraindications
severe anaemia; severe bone marrow depression; pregnancy; breastfeeding
- Minor side effects
nausea; diarrhoea; constipation
- Moderate side effects
anaemia; leukopenia; thrombocytopenia
- Dosage forms
Tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Bristol-Myers Squibb
- Onset Time
1–2 weeks
- Duration
long-term
- Storage instructions
Store at room temperature, away from moisture and heat.
- Drug interactions
zidovudine; didanosine; stavudine
- Age restrictions
Consult specialist regarding paediatric use.
Precautions and warnings
regular blood count monitoring is essential; maintain adequate hydration; use effective contraception
Serious side effects
pulmonary fibrosis — requires immediate medical attention; cutaneous vasculitis — requires immediate medical attention; secondary malignancy — requires immediate medical attention
Patient summary
Formulated to target cancerous cell growth and indicated to support blood count regulation, this agent is utilized to manage specific haematologic conditions.
Mechanism of action
Hydroxycarbamide acts as an antimetabolite that inhibits ribonucleotide reductase, an essential enzyme for DNA synthesis. By blocking this process, it halts the replication of rapidly dividing cells, effectively slowing disease progression in haematologic malignancies.
Pregnancy and breastfeeding
Pregnancy: Must not be used during pregnancy. Breastfeeding: Must not be used while breastfeeding.
Hydroxyurea Tablets
Formulated to target cancerous cell growth and indicated to support blood count regulation, this agent is utilized to manage specific haematologic conditions.
Editorial Notes
- Active ingredient(s): Hydroxycarbamide
- Listed indication(s): Chronic Myeloid Leukaemia, Polycythaemia Vera, Essential Thrombocythaemia
Available option
- 60 tablets - 500 mg1395-500-mg-16733